Kiniksa Pharmaceuticals Ltd (KNSA)
20.33
+0.34
(+1.70%)
USD |
NASDAQ |
May 07, 16:00
20.33
0.00 (0.00%)
After-Hours: 20:00
Kiniksa Pharmaceuticals Revenue (Quarterly): 79.86M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 79.86M |
| December 31, 2023 | 83.40M |
| September 30, 2023 | 67.05M |
| June 30, 2023 | 71.47M |
| March 31, 2023 | 48.34M |
| December 31, 2022 | 61.88M |
| Date | Value |
|---|---|
| September 30, 2022 | 99.14M |
| June 30, 2022 | 26.97M |
| March 31, 2022 | 32.19M |
| December 31, 2021 | 18.74M |
| September 30, 2021 | 12.10M |
| June 30, 2021 | 7.704M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
7.704M
Minimum
Jun 2021
99.14M
Maximum
Sep 2022
50.74M
Average
55.11M
Median
Revenue (Quarterly) Benchmarks
| Amicus Therapeutics Inc | 115.08M |
| Geron Corp | 0.304M |
| United Therapeutics Corp | 677.70M |
| Vanda Pharmaceuticals Inc | 45.27M |
| TG Therapeutics Inc | 63.47M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -17.70M |
| Total Expenses (Quarterly) | 96.40M |
| EPS Diluted (Quarterly) | -0.25 |
| Enterprise Value | 1.229B |
| Gross Profit Margin (Quarterly) | 60.70% |
| Profit Margin (Quarterly) | -22.17% |
| Earnings Yield | 0.54% |
| Normalized Earnings Yield | 0.5411 |